Status:
COMPLETED
Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients
Lead Sponsor:
Fred Hutchinson Cancer Center
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Leukemia
Hodgkin Disease
Eligibility:
All Genders
18+ years
Brief Summary
The investigators are interested in identifying patient-specific factors related to donor chimerism in patients who receive nonmyeloablative hematopoietic stem cell transplants from haploidentical don...
Eligibility Criteria
Inclusion
- Scheduled to receive nonmyeloablative conditioning which includes fludarabine
- Scheduled to receive a haploidentical graft
- Scheduled to receive postgrafting immunosuppression which includes oral mycophenolate mofetil (MMF) or enteric-coated mycophenolic acid
- Age \>18 years at the time of enrollment
Exclusion
- Diagnosed with an immunodeficiency disorder, including HIV
Key Trial Info
Start Date :
May 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT01141959
Start Date
May 1 2010
End Date
December 1 2011
Last Update
May 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109